Clinical Trial Services for Generic Drug Development

The global generic pharmaceutical industry plays a crucial role in healthcare, comprising over 90% of prescriptions in the U.S. and supplying around 20% of the world's generics from India. These affordable drugs enhance patient access to essential medicines, allowing healthcare systems to manage costs while providing quality care. However, successfully launching a generic drug requires more than proving bioequivalence; it involves ensuring high clinical trial quality, regulatory compliance, participant safety, and dependable data, highlighting the necessity of robust clinical trial services.

Zenovel provides comprehensive clinical trial services for generic drug development, blending scientific rigor, regulatory expertise, and operational excellence to support sponsors in effectively navigating this intricate landscape.

Challenges of Generic Drug Development

Generic drug development follows an abbreviated pathway yet adheres to rigorous clinical and regulatory standards. The Abbreviated New Drug Application (ANDA) enables generics to be approved by proving therapeutic equivalence to a Reference Listed Drug (RLD) without full-scale clinical trials. The focus is on demonstrating bioequivalence (BE), which scientifically establishes that the generic drug delivers the same active ingredient into the bloodstream at comparable rates to the reference product. BE studies utilize pharmacokinetic parameters like AUC and Cmax, requiring an 80–125% range relative to the reference.

Even straightforward bioequivalence studies necessitate robust processes to maintain data integrity and compliance, facing significant challenges.

Organizations lacking proper oversight may encounter protocol deviations, delayed approvals, inspection findings, and rising development costs.

 ICH M13A:

A landmark shift occurred in January 2025 with the implementation of the ICH M13A guideline on bioequivalence for immediate-release solid oral dosage forms, harmonizing global standards for oral tablets and capsules, adopted by both the FDA and EMA.

Key provisions of ICH M13A include:

Manufacturers of oral tablets and capsules now require only one bioequivalence study, instead of multiple tests, which lowers time and costs for generics to market. This harmonization enhances efficiency and supports quicker access to safe, effective generic drugs globally.

Zenovel Supports Generic Drug Development

Zenovel provides comprehensive clinical trial services ranging from Phase I to IV, encompassing patient-based BE and pharmacokinetic (PK) studies, along with customized therapeutic research. With years of experience and a global footprint in regions such as India, the USA, Canada, and the EU, Zenovel offers exceptional expertise in its field.

Bioequivalence Study Services

Zenovel specializes in creating scientifically sound and regulatory-compliant study protocols, forming the backbone of successful BE studies. We offer tailored independent monitoring services, supported by experienced GCP experts, to ensure effective clinical trial conduct. The PK-Stat review translates complex pharmacokinetic data into compelling regulatory evidence, connecting biological insights to necessary regulatory acceptance. Additionally, Zenovel implements innovative RBM strategies to enhance trial efficiency, prioritize high-risk areas, and maintain patient safety, data integrity, and compliance, all while reducing costs and timelines.

 Clinical Monitoring Services

Clinical monitoring is essential in clinical trial management, providing oversight to ensure adherence to protocols, regulatory standards, and GCP guidelines. For generic drug manufacturers, it verifies the accuracy of study data, adherence to protocols by investigators, participant safety, compliance with regulatory requirements, and readiness of clinical trial documentation for inspection.

Regulatory Affairs Services

Zenovel's regulatory team specializes in navigating global regulatory frameworks, ensuring timely submissions with full compliance documentation. Key services include dossier preparation for ANDAs, NDAs, INDs, and MAAs; customized CTD templates; regulatory strategy development and gap assessments; expertise in eCTD software for EU and US submissions; and extensive post-approval submission support, having completed over submissions and MAAs.

 GCP Audits

Before outsourcing BA/BE studies to a CRO, it is crucial to perform a GCP audit to guarantee compliance and quality. Zenovel offers various GCP audits, including CRO qualification, vendor qualification, investigator site, study-specific, gap, quality assurance, safety assessment, and pre-inspection readiness audits, ensuring full regulatory compliance in clinical research.

CRO Setup and Upgradation

Zenovel enables GCP-compliant setup and maintenance for CROs, focusing on vendor management, process optimization, QMS implementation, infrastructure development, and regulatory compliance, thereby improving efficiency, quality, and adherence to regulations.

In the competitive generic pharmaceutical market, success hinges on more than just manufacturing; effective clinical trial services are essential for launching generic drugs. Zenovel combines scientific expertise, regulatory knowledge, and operational capabilities to assist generic manufacturers in navigating this complex environment. With a strong track record and commitment to quality, Zenovel provides integrated services that expedite approvals, ensuring patients receive affordable medicines more quickly.

Ready to accelerate your generic drug development program? Contact Zenovel today to learn how their comprehensive clinical trial services can support your next submission.